Nanoscope advances gene-agnostic therapy for severe vision loss in RP

Nanoscope Therapeutics' Biologics License Application for MOGENRY, a gene-agnostic optogenetic gene therapy for retinitis pigmentosa with severe vision loss, has been accepted by the FDA based on positive Phase 2b/3 RESTORE trial and long-term REMAIN follow-up study data.

This Wire brief sits within Fusion42's coverage of Biotech.